30 years of historical data (1996–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Regeneron Pharmaceuticals, Inc. trades at 18.8x earnings, roughly in line with its 5-year average of 18.0x, sitting at the 40th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 20%. On a free-cash-flow basis, the stock trades at 26.4x P/FCF, 32% above the 5-year average of 19.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $107.6B | $83.8B | $82.0B | $99.9B | $81.9B | $70.9B | $55.6B | $43.0B | $42.9B | $43.6B | $42.7B |
| Enterprise Value | $91.4B | $67.7B | $82.2B | $99.8B | $81.5B | $70.7B | $56.1B | $42.1B | $42.1B | $43.5B | $42.6B |
| P/E Ratio → | 18.84 | 18.61 | 18.58 | 25.26 | 18.88 | 8.77 | 15.83 | 20.34 | 17.54 | 36.36 | 47.67 |
| P/S Ratio | 7.50 | 5.84 | 5.77 | 7.61 | 6.73 | 4.41 | 6.54 | 6.56 | 6.39 | 7.42 | 8.78 |
| P/B Ratio | 2.72 | 2.68 | 2.79 | 3.84 | 3.61 | 3.78 | 5.04 | 3.88 | 4.90 | 7.09 | 9.60 |
| P/FCF | 26.36 | 20.54 | 22.37 | 27.23 | 18.51 | 10.85 | 27.75 | 21.51 | 23.66 | 42.12 | 43.83 |
| P/OCF | 21.60 | 16.84 | 18.55 | 21.74 | 16.33 | 10.01 | 21.24 | 17.71 | 19.53 | 33.34 | 28.73 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Regeneron Pharmaceuticals, Inc.'s enterprise value stands at 21.6x EBITDA, 40% above its 5-year average of 15.4x. The Healthcare sector median is 13.8x, placing the stock at a 56% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.72 | 5.79 | 7.61 | 6.69 | 4.40 | 6.60 | 6.42 | 6.28 | 7.40 | 8.77 |
| EV / EBITDA | 21.64 | 16.02 | 18.38 | 20.93 | 14.23 | 7.65 | 14.72 | 17.41 | 15.70 | 19.54 | 29.70 |
| EV / EBIT | 24.75 | 12.83 | 17.00 | 23.37 | 16.57 | 7.53 | 14.51 | 17.13 | 16.31 | 20.66 | 31.89 |
| EV / FCF | — | 16.58 | 22.43 | 27.22 | 18.42 | 10.82 | 28.00 | 21.06 | 23.24 | 42.02 | 43.78 |
Margins and return-on-capital ratios measuring operating efficiency
Regeneron Pharmaceuticals, Inc. earns an operating margin of 25.7%. Operating margins have compressed from 33.2% to 25.7% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 14.9% is modest. ROIC of 12.4% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.3% | 86.3% | 86.1% | 82.9% | 86.0% | 83.1% | 84.0% | 85.1% | 91.3% | 90.8% | 91.7% |
| Operating Margin | 25.7% | 25.7% | 28.1% | 33.2% | 44.2% | 55.7% | 42.1% | 33.7% | 37.8% | 35.4% | 27.4% |
| Net Profit Margin | 31.4% | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 32.3% | 36.4% | 20.4% | 18.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 14.9% | 14.9% | 16.0% | 16.3% | 20.9% | 54.2% | 31.8% | 21.3% | 32.8% | 22.6% | 22.1% |
| ROA | 11.5% | 11.5% | 12.5% | 12.7% | 15.9% | 37.9% | 22.0% | 15.9% | 23.8% | 15.2% | 14.2% |
| ROIC | 12.4% | 12.4% | 10.8% | 13.5% | 19.8% | 44.6% | 24.7% | 18.2% | 27.1% | 29.9% | 26.2% |
| ROCE | 10.8% | 10.8% | 12.6% | 15.6% | 22.6% | 49.7% | 26.3% | 19.2% | 28.3% | 31.1% | 25.3% |
Solvency and debt-coverage ratios — lower is generally safer
Regeneron Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 0.6x, which is very conservative (79% below the sector average of 3.1x). The company holds a net cash position — cash of $18.9B exceeds total debt of $2.7B, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 84.3x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.09 | 0.10 | 0.12 | 0.14 | 0.24 | 0.06 | 0.08 | 0.11 | 0.11 |
| Debt / EBITDA | 0.64 | 0.64 | 0.60 | 0.57 | 0.47 | 0.29 | 0.71 | 0.29 | 0.26 | 0.32 | 0.34 |
| Net Debt / Equity | — | -0.52 | 0.01 | -0.00 | -0.02 | -0.01 | 0.05 | -0.08 | -0.09 | -0.02 | -0.01 |
| Net Debt / EBITDA | -3.83 | -3.83 | 0.05 | -0.01 | -0.07 | -0.02 | 0.13 | -0.37 | -0.28 | -0.05 | -0.04 |
| Debt / FCF | — | -3.96 | 0.06 | -0.01 | -0.09 | -0.03 | 0.25 | -0.45 | -0.42 | -0.11 | -0.06 |
| Interest Coverage | 84.31 | 84.31 | 72.30 | 59.57 | 90.67 | 156.14 | 62.86 | 73.17 | 89.87 | 82.79 | 184.95 |
Net cash position: cash ($18.9B) exceeds total debt ($2.7B)
Short-term solvency ratios and asset-utilisation metrics
Regeneron Pharmaceuticals, Inc.'s current ratio of 4.77x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 4.22x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.69x to 4.77x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.77 | 4.77 | 4.73 | 5.69 | 5.06 | 3.56 | 3.63 | 3.67 | 5.52 | 4.93 | 3.15 |
| Quick Ratio | 4.22 | 4.22 | 3.95 | 4.94 | 4.29 | 3.07 | 2.91 | 2.99 | 4.72 | 4.29 | 2.83 |
| Cash Ratio | 3.23 | 3.23 | 2.28 | 3.17 | 2.46 | 1.45 | 1.33 | 1.53 | 1.95 | 1.24 | 0.84 |
| Asset Turnover | — | 0.35 | 0.38 | 0.40 | 0.42 | 0.63 | 0.50 | 0.44 | 0.57 | 0.67 | 0.70 |
| Inventory Turnover | 0.62 | 0.62 | 0.64 | 0.87 | 0.71 | 1.40 | 0.71 | 0.69 | 0.51 | 0.75 | 1.01 |
| Days Sales Outstanding | — | 146.10 | 159.65 | 157.70 | 159.78 | 137.09 | 176.75 | 155.05 | 122.01 | 122.72 | 121.03 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Regeneron Pharmaceuticals, Inc. returns 3.6% to shareholders annually — split between a 0.4% dividend yield and 3.2% buyback yield. The earnings yield of 5.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.4% | 0.4% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.3% | 5.4% | 5.4% | 4.0% | 5.3% | 11.4% | 6.3% | 4.9% | 5.7% | 2.8% | 2.1% |
| FCF Yield | 3.8% | 4.9% | 4.5% | 3.7% | 5.4% | 9.2% | 3.6% | 4.6% | 4.2% | 2.4% | 2.3% |
| Buyback Yield | 3.2% | 4.1% | 4.4% | 2.9% | 3.1% | 3.8% | 11.7% | 1.1% | 0.4% | 0.7% | 0.3% |
| Total Shareholder Yield | 3.6% | 4.5% | 4.4% | 2.9% | 3.1% | 3.8% | 11.7% | 1.1% | 0.4% | 0.7% | 0.3% |
| Shares Outstanding | — | $109M | $115M | $114M | $114M | $112M | $115M | $115M | $115M | $116M | $116M |
Compare REGN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| REGNYou | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| TECX | $439M | -6.0 | — | — | — | — | -206.6% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how REGN stacks up against sector leader Centessa Pharmaceuticals plc.
Start ComparisonRegeneron Pharmaceuticals, Inc.'s current P/E ratio is 18.8x. The historical average is 38.4x. This places it at the 40th percentile of its historical range.
Regeneron Pharmaceuticals, Inc.'s current EV/EBITDA is 21.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 25.5x.
Regeneron Pharmaceuticals, Inc.'s return on equity (ROE) is 14.9%. The historical average is -3.0%.
Based on historical data, Regeneron Pharmaceuticals, Inc. is trading at a P/E of 18.8x. This is at the 40th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Regeneron Pharmaceuticals, Inc.'s current dividend yield is 0.44%.
Regeneron Pharmaceuticals, Inc. has 86.3% gross margin and 25.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Regeneron Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 0.6x, indicating low leverage. A ratio below 2x is generally considered financially healthy.